CAPTAIN data shows TULSA-PRO halves surgical harm vs. robotic prostatectomy; survival to cash-flow breakeven determines whether the commercial story completes

Profound Medical is a commercial-stage medical device company developing TULSA-PRO, an ultrasound-based treatment for localized prostate cancer that is not yet approved by major regulatory bodies but has generated clinical trial data supporting its use.

TULSA-PRO, a transurethral ultrasound ablation system for localized prostate cancer, just posted Level 1 randomized data showing 50% versus 24% preservation of both continence and erectile function against robotic prostatectomy. Revenue growing at 56% guidance with 78% gross margins and expanding payer coverage is the commercial engine, but $38M cash at roughly $10M quarterly burn reaches only Q2 2027. The thesis resolves on whether revenue accelerates fast enough to avoid a dilutive raise before breakeven, with payer adoption breadth the single variable most likely to determine that outcome.